Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by Accountprinceon Dec 13, 2022 9:38am
237 Views
Post# 35168123

RE:RE:Press Release

RE:RE:Press ReleaseTo state the obvious they screwed up with compliance under the agreement with Infomed.  On a "when not if" for DIMI and full FDA approval for SAMI.  A measly 35 to be run through for the DIMI trial.  Sites on board and everything.  All paid for by us.

Infomed called them out for their pathetic handling of this.  At least Infomed knows the value of what we used to have 100% of.  Infomed grabbed the fumble near the five yard line and is assured of a touchdown.  A position we should have been at.  Now we get a measly 30% of the value.  Hey Seto is this agreement going to be redacted too?

Let's start the negotiation with Baxter to sell everything related to PMX.  But first we need some capable personnel to be at the negotiating table.  Fire the amateurs.  Then sell because this lot is not capable of anything.  Proven beyond the shadow of any doubt now.
<< Previous
Bullboard Posts
Next >>